Leadd B.v.

Gerden F De Boer

Mathews H M Noteborn

Mathews Hm Noteborn

Recombinant genetic information (DNA or RNA), comprising a Chicken Anemia Virus (CAV)-specific nucleotide sequence and the use thereof for diagnostics, vaccination or protein production. Recombinant CAV protein and the use thereof for diagnostics, vaccination or production of CAV-specific antibodies. The use of CAV-specific antibodies thus obtained.

Cloning of chicken anemia DNA

Circular double-stranded replication intermediates were identified in low-molecular-weight DNA of cells of the avian leukemia virus-induced lymphoblastoid cell line 1104-X-5 infected with chicken anemia virus (CAV). To characterize the genome of CAV, we cloned linearized CAV DNA into the vector pIC20H. Transfection of the circularized cloned insert into chicken cell lines caused a cytopathogenic effect, which was arrested when a chicken serum with neutralizing antibodies directed against CAV was added. The 2,319-bp cloned CAV DNA contained all the genetic information needed for the complete replication cycle of CAV. The CAV genome probably contains only one promoter region and only one poly(A) addition signal. Southern blot analysis using oligomers derived from the CAV DNA sequence showed that infected cells contained double- and single-stranded CAV DNAs, whereas purified virus contained only the minus strand. The CAV DNA sequence has three partially overlapping major reading frames coding for putative peptides of 51.6, 24.0, and 13.6 kDa. The claimed invention is directed toward immunogenic and vaccine compositions comprising these novel peptides.

Proteins encoded by chicken anemia virus DNA and diagnostic kits and vaccines employing said proteins

Recombinant chicken anemia virus particle

Recombinant genetic information (DNA or RNA), comprising a Chicken Anemia Virus (CAV)-specific nucleotide sequence and the use thereof for diagnostics, vaccination or protein production are described. Recombinant CAV protein and the use thereof for diagnostics, vaccination or production of CAV-specific antibodies, and use of CAV-specific antibodies thus obtained, are also described. The cloned complete CAV DNA genome disclosed is representative of CAV in the field, worldwide. By means of PCR with primers derived from the cloned CAV genome, CAV-specific sequences corresponding with or complementary to the nucleotide sequence described can be detected. CAV harbors a specific promoter/enhancer element which regulates the CAV transcriptional activity. Based upon this, a sensitive CAV-specific PCR and a method for validating negative PCR results and for estimating the number of CAV DNA copies present in the analyzed sample have been developed.

Growing community of inventors

Lelystad, Netherlands

Gerden F De Boer